Lumida
/BMRN
⌘K
BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

BMRN
$59.59USD↓-0.68%-0.41 today

MARKET CAP

11.5B

P/E (TTM)

43.5x

FWD P/E

11.6x

DAY RANGE

$59 – $61

52W RANGE

$49
$66

AI Summary

Stalk
Buy NowMedium

BMRN is in an early Stage 1 basing attempt with a fragile but constructive repair of the 9/21 EMAs and an active Lockout Rally pattern driving medium-term bullish asymmetry. Despite overbought context near prior resistance, price remains accepted above the rising EMAs, confirming continuation bias. Short-term readiness is strong now, supported by a pullback and consolidation into EMAs. Buy Now to participate in the urgency-driven repricing.

  • ↑VoxOgo sales grew 20% YoY to $221 M in Q2 and full-year revenues guided to $3.325–3.425 B.
  • ↑FDA’s sNDA acceptance for full VoxOgo approval paves way for 2027 market expansion.
  • ↓Weak profitability factors signal inefficiency converting revenue into profits amid rising costs.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a leading biotechnology company dedicated to developing innovative therapies targeting severe genetic diseases. The firm specializes in enzyme replacement therapies, particularly in pediatric populations, addressing significant unmet medical needs. BioMarin is also expanding its potential through strategic acquisitions, like the recent purchase of Amicus Therapeutics, which enhances its competitive positioning in the biopharmaceutical landscape.

Bull says

  • ↑VoxOgo sales grew 20% YoY to $221 M in Q2 and full-year revenues guided to $3.325–3.425 B.
  • ↑FDA’s sNDA acceptance for full VoxOgo approval paves way for 2027 market expansion.
  • ↑Amicus acquisition adds ~$500 M revenue and diversifies pipeline for 2026.
  • ↑New patient starts for VoxOgo doubled, boosting under-two adoption rates.
  • ↑Pipeline advances in hypochondroplasia and BMN 333 drive R&D upside.
  • ↑High earnings yield, strong growth factors, favorable book-to-price, positive liquidity and low leverage risk.

Bear says

  • ↓Weak profitability factors signal inefficiency converting revenue into profits amid rising costs.
  • ↓Novel achondroplasia therapies could erode VoxOgo’s market share and growth trajectory.
  • ↓Order-timing variability poses revenue consistency and guidance risk.
  • ↓Amicus deal carries near-term dilution and integration risks to EPS.
  • ↓Patient adherence uncertainty amid competition may pressure future sales.
  • ↓Negative momentum factors and lack of dividend yield deter income-focused investors.

Investment themes with BMRN

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-17-2026bullish

Transcript signals

Bull points

  • We were encouraged by the commercial execution across our portfolio so far this year, with strong patient demand across enzyme therapies and Voxogo.
  • We look forward to providing a more detailed commercial update on our plans to maximize the potential of both Gallifold and Pompility and Upholda next quarter.
  • Across the enzyme therapies portfolio, we continue to see strong patient demand and adherence.

Bear points

  • cost of sales increased year over year in the first quarter, primarily due to a $31 million charge associated with an unsuccessful process qualification campaign to extend Nagozyme manufacturing capabilities. Importantly, this did not impact commercial supply.
Read full transcript analysis ›